Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This is an efficacy and safety study of Vytorin (ezetimibe (+) simvastatin) compared to
atorvastatin (ezetimibe/simvastatin) at week 6 in primary hypercholesterolemia patients in
Korea. The primary hypothesis being tested is that daily administration of Vytorin will
result in a greater reduction of low density lipoprotein cholesterol (LDL-C) concentration
from baseline after 6 weeks treatment compared to atorvastatin.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Atorvastatin Atorvastatin Calcium Ezetimibe Ezetimibe, Simvastatin Drug Combination Simvastatin